Abstract | BACKGROUND: METHODS: A MEDLINE search, limited to human clinical trials and using the search criteria 'GLP-1RA' or 'DPP-4 inhibitor', identified seven head-to-head studies and one relevant post hoc analysis (all a GLP-1RA vs. the DPP-4 inhibitor sitagliptin). In combination with treatment algorithms, product prescribing information and personal clinical experience, these studies were used to compare the efficacy and suitability of GLP-1RAs and DPP-4 inhibitors in patients with T2D. RESULTS: In head-to-head clinical trials, GLP-1RAs provided greater glycaemic control, weight loss and overall treatment satisfaction vs. the DPP-4 inhibitor sitagliptin. Transient nausea was more frequent with GLP-1RAs and should be addressed through patient education and an incremental dosing approach. Current treatment algorithms recommend incretin-based therapy use after metformin failure, but local guidance may restrict their use. CONCLUSION:
|
Authors | S Brunton |
Journal | International journal of clinical practice
(Int J Clin Pract)
Vol. 68
Issue 5
Pg. 557-67
(May 2014)
ISSN: 1742-1241 [Electronic] India |
PMID | 24499291
(Publication Type: Comparative Study, Journal Article, Review)
|
Copyright | © 2014 The Authors International Journal of Clinical Practice Published by John Wiley & Sons Ltd. |
Chemical References |
- Dipeptidyl-Peptidase IV Inhibitors
- Glucagon-Like Peptide-1 Receptor
- Hypoglycemic Agents
|
Topics |
- Diabetes Mellitus, Type 2
(drug therapy)
- Dipeptidyl-Peptidase IV Inhibitors
(therapeutic use)
- Glucagon-Like Peptide-1 Receptor
(antagonists & inhibitors)
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Treatment Outcome
|